Tazarotene
Tazarotene is a synthetic acetylenic retinoid that selectively binds to retinoic acid receptors RARβ and RARγ, modulating gene expression to normalize keratinocyte proliferation and differentiation. It is used topically for plaque psoriasis, acne vulgaris, and photoaging, and is under investigation for certain skin cancers and as part of combination regimens for bladder and breast cancers. Its receptor selectivity aims to provide efficacy while minimizing systemic retinoid-associated adverse effects.
Molecular Weight
351.5000 g/mol
LogP
4.90
TPSA
64.50 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
2D Structure
Cite this structure
Embed this structure
SMILES
CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
InChI
InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3
Molecular Formula
C21H21NO2S
HBD / HBA
- / 4
Rotatable Bonds
5
Heavy Atoms
25
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Tazarotene is a synthetic acetylenic retinoid that selectively binds to retinoic acid receptors RARβ and RARγ, modulating gene expression to normalize keratinocyte proliferation and differentiation. It is used topically for plaque psoriasis, acne vulgaris, and photoaging, and is under investigation for certain skin cancers and as part of combination regimens for bladder and breast cancers. Its receptor selectivity aims to provide efficacy while minimizing systemic retinoid-associated adverse effects.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Tazarotene is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1657. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5381. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tazarotene"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tazarotene/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tazarotene/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tazarotene/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tazarotene"></drugfyi-drug>